Predicting survival using clinical risk scores and non-HLA immunogenetics
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26214138
DOI
10.1038/bmt.2015.173
PII: bmt2015173
Knihovny.cz E-zdroje
- MeSH
- alfa receptor estrogenů genetika MeSH
- alografty MeSH
- dítě MeSH
- dospělí MeSH
- genotyp MeSH
- haplotypy MeSH
- hematologické nádory mortalita terapie MeSH
- histokompatibilita MeSH
- hodnocení rizik metody MeSH
- infekce mortalita MeSH
- interleukin-10 genetika MeSH
- interleukin-6 genetika MeSH
- jednonukleotidový polymorfismus * MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- membránové glykoproteiny genetika MeSH
- mladiství MeSH
- multiorgánové selhání mortalita MeSH
- následné studie MeSH
- nemoc štěpu proti hostiteli mortalita MeSH
- příčina smrti MeSH
- příprava pacienta k transplantaci škodlivé účinky MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- receptory interleukinu-1 genetika MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk mortalita MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- alfa receptor estrogenů MeSH
- ESR1 protein, human MeSH Prohlížeč
- IL10 protein, human MeSH Prohlížeč
- IL6 protein, human MeSH Prohlížeč
- interleukin-10 MeSH
- interleukin-6 MeSH
- membránové glykoproteiny MeSH
- receptory interleukinu-1 MeSH
- TIRAP protein, human MeSH Prohlížeč
Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single-nucleotide polymorphisms (SNPs) on subgroups of patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) revealed an association with transplant outcome. This study further evaluated the association of non-HLA polymorphisms with overall survival in a cohort of 762 HSCT patients using data on 26 polymorphisms in 16 non-HLA genes. When viewed in addition to an already established clinical risk score (EBMT-score), three polymorphisms: rs8177374 in the gene for MyD88-adapter-like (MAL; P=0.026), rs9340799 in the oestrogen receptor gene (ESR; P=0.003) and rs1800795 in interleukin-6 (IL-6; P=0.007) were found to be associated with reduced overall survival, whereas the haplo-genotype (ACC/ACC) in IL-10 was protective (P=0.02). The addition of these non-HLA polymorphisms in a Cox regression model alongside the EBMT-score improved discrimination between risk groups and increased the level of prediction compared with the EBMT-score alone (gain in prediction capability for EBMT-genetic-score 10.8%). Results also demonstrated how changes in clinical practice through time have altered the effects of non-HLA analysis. The study illustrates the significance of non-HLA genotyping prior to HSCT and the importance of further investigation into non-HLA gene polymorphisms in risk prediction.
Departement d'Immunologie Université Paris Diderot INSERM UMRS 940 AP HP Paris France
Department 1 of Internal Medicine University of Cologne Cologne Germany
Department of Bone Marrow Transplantation EUROCORD St Louis Hospital Paris France
Department of Cellular and Molecular Immunology University Medical Center Göttingen Germany
Department of Genetic Epidemiology University Medical Center Göttingen Germany
Department of Haematology and Oncology Klinikum Grosshadern Medical Klinik 3 Munich Germany
Department of Haematology Division of Haematology Medical University of Graz Graz Austria
Department of Hematology and Oncology University of Regensburg Regensburg Germany
Zobrazit více v PubMed
Transplantation. 2003 Dec 27;76(12):1742-9 PubMed
Haematologica. 2006 Apr;91(4):513-21 PubMed
J Biol Chem. 1994 Mar 18;269(11):8159-64 PubMed
J Clin Invest. 1998 Oct 1;102(7):1369-76 PubMed
Haematologica. 2006 Jun;91(6):848-51 PubMed
Bone Marrow Transplant. 2012 Jun;47(6):749-56 PubMed
Bone Marrow Transplant. 2003 Jul;32(1):41-7 PubMed
Blood. 2013 Nov 7;122(19):3365-75 PubMed
Blood. 2007 Feb 15;109(4):1355-62 PubMed
Clin Mol Allergy. 2006 Jun 07;4:9 PubMed
JAMA. 1982 May 14;247(18):2543-6 PubMed
Differentiation. 1997 Feb;61(3):177-85 PubMed
Lancet. 1998 Oct 3;352(9134):1087-92 PubMed
Curr Opin Hematol. 2010 Nov;17(6):483-92 PubMed
Br J Haematol. 2004 Dec;127(5):479-90 PubMed
Stat Med. 1984 Apr-Jun;3(2):143-52 PubMed
Int J Immunogenet. 2008 Aug;35(4-5):375-80 PubMed
Blood. 2004 Aug 1;104(3):889-94 PubMed
Haematologica. 2010 Jun;95(6):922-7 PubMed
J Rheumatol. 2001 Nov;28(11):2383-8 PubMed
Am J Hum Genet. 2007 Feb;80(2):273-90 PubMed
Blood. 2002 Dec 1;100(12):3908-18 PubMed
Eur J Immunol. 1998 Aug;28(8):2598-602 PubMed
Ann Surg Oncol. 2007 May;14(5):1670-7 PubMed
Stroke. 2011 Mar;42(3):588-92 PubMed
Eur J Immunogenet. 1997 Feb;24(1):1-8 PubMed
J Clin Endocrinol Metab. 2004 Feb;89(2):892-7 PubMed
Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 PubMed
Blood. 2012 May 31;119(22):5311-9 PubMed
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3386-93 PubMed
Bone Marrow Transplant. 2002 Aug;30(4):223-8 PubMed
Differentiation. 1997 Nov;62(2):97-105 PubMed
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 PubMed
N Engl J Med. 2003 Dec 4;349(23):2201-10 PubMed
Bone Marrow Transplant. 2005 Dec;36(12):1089-95 PubMed
J Rheumatol. 2006 Apr;33(4):703-8 PubMed
Clin Pharmacol Ther. 2001 Aug;70(2):189-99 PubMed
Blood. 2001 Sep 1;98(5):1594-600 PubMed
Nat Rev Immunol. 2004 Jul;4(7):499-511 PubMed
Int J Mol Epidemiol Genet. 2010 Feb 20;1(2):104-13 PubMed
PLoS One. 2011 Jan 28;6(1):e16582 PubMed
Scand J Gastroenterol. 2002 Feb;37(2):189-91 PubMed
Cytokine. 1999 Oct;11(10):789-95 PubMed
Transplantation. 2005 Apr 15;79(7):815-20 PubMed
Genes Immun. 2009 Jun;10 (4):365-72 PubMed
Eur J Immunogenet. 1999 Feb;26(1):1-3 PubMed
J Allergy Clin Immunol. 2000 Mar;105(3):506-13 PubMed
J Clin Invest. 1992 Mar;89(3):883-91 PubMed
J Med Genet. 1996 Aug;33(8):689-92 PubMed
Cancer. 2009 Oct 15;115(20):4715-26 PubMed
Bone Marrow Transplant. 2009 Aug;44(4):227-35 PubMed
